(+)-4-PROPYL-9-HYDROXYNAPHTHOXAZINE (PHNO), A NEW DOPAMINOMIMETIC, IN TREATMENT OF PARKINSONISM
Identifieur interne : 000738 ( Istex/Corpus ); précédent : 000737; suivant : 000739(+)-4-PROPYL-9-HYDROXYNAPHTHOXAZINE (PHNO), A NEW DOPAMINOMIMETIC, IN TREATMENT OF PARKINSONISM
Auteurs : A. Jon Stoessl ; E. Mak ; Donaldb. CalneSource :
- The Lancet [ 0140-6736 ] ; 1985.
Abstract
PHNO is a naphthoxazine compound with selective D2 agonist properties and a molecular structure unrelated to the morphine and ergot derivatives that have been used to treat Parkinson's disease. A double-blind, dose-ranging study on 8 patients showed that it is effective in the treatment of parkinsonism; its duration of effect of up to 6 h could make it useful for patients who experience wearing-off reactions with levodopa.
Url:
DOI: 10.1016/S0140-6736(85)92627-3
Links to Exploration step
ISTEX:3F63D38FCCAE9F923B30538459CCC8C55B38697DLe document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title>(+)-4-PROPYL-9-HYDROXYNAPHTHOXAZINE (PHNO), A NEW DOPAMINOMIMETIC, IN TREATMENT OF PARKINSONISM</title><author><name sortKey="Stoessl, A Jon" sort="Stoessl, A Jon" uniqKey="Stoessl A" first="A. Jon" last="Stoessl">A. Jon Stoessl</name><affiliation><mods:affiliation>Division of Neurology, Department of Medicine, University of British Columbia Health Sciences Centre Hospital, 2211 Wesbrook Mall, Vancouver, British Columbia V6T 1W5, Canada</mods:affiliation></affiliation></author><author><name sortKey="Mak, E" sort="Mak, E" uniqKey="Mak E" first="E." last="Mak">E. Mak</name><affiliation><mods:affiliation>Division of Neurology, Department of Medicine, University of British Columbia Health Sciences Centre Hospital, 2211 Wesbrook Mall, Vancouver, British Columbia V6T 1W5, Canada</mods:affiliation></affiliation></author><author><name sortKey="Calne, Donaldb" sort="Calne, Donaldb" uniqKey="Calne D" first="Donaldb." last="Calne">Donaldb. Calne</name><affiliation><mods:affiliation>Division of Neurology, Department of Medicine, University of British Columbia Health Sciences Centre Hospital, 2211 Wesbrook Mall, Vancouver, British Columbia V6T 1W5, Canada</mods:affiliation></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:3F63D38FCCAE9F923B30538459CCC8C55B38697D</idno><date when="1985" year="1985">1985</date><idno type="doi">10.1016/S0140-6736(85)92627-3</idno><idno type="url">https://api-v5.istex.fr/document/3F63D38FCCAE9F923B30538459CCC8C55B38697D/fulltext/pdf</idno><idno type="wicri:Area/Istex/Corpus">000738</idno><idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Corpus" wicri:corpus="ISTEX">000738</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a">(+)-4-PROPYL-9-HYDROXYNAPHTHOXAZINE (PHNO), A NEW DOPAMINOMIMETIC, IN TREATMENT OF PARKINSONISM</title><author><name sortKey="Stoessl, A Jon" sort="Stoessl, A Jon" uniqKey="Stoessl A" first="A. Jon" last="Stoessl">A. Jon Stoessl</name><affiliation><mods:affiliation>Division of Neurology, Department of Medicine, University of British Columbia Health Sciences Centre Hospital, 2211 Wesbrook Mall, Vancouver, British Columbia V6T 1W5, Canada</mods:affiliation></affiliation></author><author><name sortKey="Mak, E" sort="Mak, E" uniqKey="Mak E" first="E." last="Mak">E. Mak</name><affiliation><mods:affiliation>Division of Neurology, Department of Medicine, University of British Columbia Health Sciences Centre Hospital, 2211 Wesbrook Mall, Vancouver, British Columbia V6T 1W5, Canada</mods:affiliation></affiliation></author><author><name sortKey="Calne, Donaldb" sort="Calne, Donaldb" uniqKey="Calne D" first="Donaldb." last="Calne">Donaldb. Calne</name><affiliation><mods:affiliation>Division of Neurology, Department of Medicine, University of British Columbia Health Sciences Centre Hospital, 2211 Wesbrook Mall, Vancouver, British Columbia V6T 1W5, Canada</mods:affiliation></affiliation></author></analytic><monogr></monogr><series><title level="j">The Lancet</title><title level="j" type="abbrev">LANCET</title><idno type="ISSN">0140-6736</idno><imprint><publisher>ELSEVIER</publisher><date type="published" when="1985">1985</date><biblScope unit="volume">326</biblScope><biblScope unit="issue">8468</biblScope><biblScope unit="page" from="1330">1330</biblScope><biblScope unit="page" to="1331">1331</biblScope></imprint><idno type="ISSN">0140-6736</idno></series></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">0140-6736</idno></seriesStmt></fileDesc><profileDesc><textClass></textClass><langUsage><language ident="en">en</language></langUsage></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">PHNO is a naphthoxazine compound with selective D2 agonist properties and a molecular structure unrelated to the morphine and ergot derivatives that have been used to treat Parkinson's disease. A double-blind, dose-ranging study on 8 patients showed that it is effective in the treatment of parkinsonism; its duration of effect of up to 6 h could make it useful for patients who experience wearing-off reactions with levodopa.</div></front></TEI><istex><corpusName>elsevier</corpusName><author><json:item><name>A.Jon Stoessl</name><affiliations><json:string>Division of Neurology, Department of Medicine, University of British Columbia Health Sciences Centre Hospital, 2211 Wesbrook Mall, Vancouver, British Columbia V6T 1W5, Canada</json:string></affiliations></json:item><json:item><name>E. Mak</name><affiliations><json:string>Division of Neurology, Department of Medicine, University of British Columbia Health Sciences Centre Hospital, 2211 Wesbrook Mall, Vancouver, British Columbia V6T 1W5, Canada</json:string></affiliations></json:item><json:item><name>DonaldB. Calne</name><affiliations><json:string>Division of Neurology, Department of Medicine, University of British Columbia Health Sciences Centre Hospital, 2211 Wesbrook Mall, Vancouver, British Columbia V6T 1W5, Canada</json:string></affiliations></json:item></author><language><json:string>eng</json:string></language><originalGenre><json:string>Full-length article</json:string></originalGenre><abstract>PHNO is a naphthoxazine compound with selective D2 agonist properties and a molecular structure unrelated to the morphine and ergot derivatives that have been used to treat Parkinson's disease. A double-blind, dose-ranging study on 8 patients showed that it is effective in the treatment of parkinsonism; its duration of effect of up to 6 h could make it useful for patients who experience wearing-off reactions with levodopa.</abstract><qualityIndicators><score>2.551</score><pdfWordCount>1747</pdfWordCount><pdfCharCount>11209</pdfCharCount><pdfVersion>1.2</pdfVersion><pdfPageCount>2</pdfPageCount><pdfPageSize>607 x 962 pts</pdfPageSize><refBibsNative>true</refBibsNative><abstractWordCount>67</abstractWordCount><abstractCharCount>426</abstractCharCount><keywordCount>0</keywordCount></qualityIndicators><title>(+)-4-PROPYL-9-HYDROXYNAPHTHOXAZINE (PHNO), A NEW DOPAMINOMIMETIC, IN TREATMENT OF PARKINSONISM</title><pii><json:string>S0140-6736(85)92627-3</json:string></pii><genre><json:string>research-article</json:string></genre><serie><title>Monoammes, noyaux gris centraux et syndrome de Parkinson</title><language><json:string>unknown</json:string></language><pages><first>313</first><last>325</last></pages></serie><host><title>The Lancet</title><language><json:string>unknown</json:string></language><publicationDate>1985</publicationDate><issn><json:string>0140-6736</json:string></issn><pii><json:string>S0140-6736(00)X7275-3</json:string></pii><volume>326</volume><issue>8468</issue><pages><first>1330</first><last>1331</last></pages><genre><json:string>journal</json:string></genre></host><categories><wos><json:string>science</json:string><json:string>medicine, general & internal</json:string></wos><scienceMetrix><json:string>health sciences</json:string><json:string>clinical medicine</json:string><json:string>general & internal medicine</json:string></scienceMetrix><inist><json:string>sciences appliquees, technologies et medecines</json:string><json:string>sciences biologiques et medicales</json:string><json:string>sciences medicales</json:string><json:string>pharmacologie. traitements medicamenteux</json:string></inist></categories><publicationDate>1985</publicationDate><copyrightDate>1985</copyrightDate><doi><json:string>10.1016/S0140-6736(85)92627-3</json:string></doi><id>3F63D38FCCAE9F923B30538459CCC8C55B38697D</id><fulltext><json:item><extension>pdf</extension><original>true</original><mimetype>application/pdf</mimetype><uri>https://api-v5.istex.fr/document/3F63D38FCCAE9F923B30538459CCC8C55B38697D/fulltext/pdf</uri></json:item><json:item><extension>zip</extension><original>false</original><mimetype>application/zip</mimetype><uri>https://api-v5.istex.fr/document/3F63D38FCCAE9F923B30538459CCC8C55B38697D/fulltext/zip</uri></json:item><istex:fulltextTEI uri="https://api-v5.istex.fr/document/3F63D38FCCAE9F923B30538459CCC8C55B38697D/fulltext/tei"><teiHeader><fileDesc><titleStmt><title level="a">(+)-4-PROPYL-9-HYDROXYNAPHTHOXAZINE (PHNO), A NEW DOPAMINOMIMETIC, IN TREATMENT OF PARKINSONISM</title></titleStmt><publicationStmt><authority>ISTEX</authority><publisher>ELSEVIER</publisher><availability><p>ELSEVIER</p></availability><date>1985</date></publicationStmt><notesStmt><note type="content">Section title: Preliminary Communication</note></notesStmt><sourceDesc><biblStruct type="inbook"><analytic><title level="a">(+)-4-PROPYL-9-HYDROXYNAPHTHOXAZINE (PHNO), A NEW DOPAMINOMIMETIC, IN TREATMENT OF PARKINSONISM</title><author xml:id="author-0000"><persName><forename type="first">A.Jon</forename><surname>Stoessl</surname></persName><affiliation>Division of Neurology, Department of Medicine, University of British Columbia Health Sciences Centre Hospital, 2211 Wesbrook Mall, Vancouver, British Columbia V6T 1W5, Canada</affiliation></author><author xml:id="author-0001"><persName><forename type="first">E.</forename><surname>Mak</surname></persName><affiliation>Division of Neurology, Department of Medicine, University of British Columbia Health Sciences Centre Hospital, 2211 Wesbrook Mall, Vancouver, British Columbia V6T 1W5, Canada</affiliation></author><author xml:id="author-0002"><persName><forename type="first">DonaldB.</forename><surname>Calne</surname></persName><affiliation>Division of Neurology, Department of Medicine, University of British Columbia Health Sciences Centre Hospital, 2211 Wesbrook Mall, Vancouver, British Columbia V6T 1W5, Canada</affiliation></author><idno type="istex">3F63D38FCCAE9F923B30538459CCC8C55B38697D</idno><idno type="DOI">10.1016/S0140-6736(85)92627-3</idno><idno type="PII">S0140-6736(85)92627-3</idno></analytic><monogr><title level="j">The Lancet</title><title level="j" type="abbrev">LANCET</title><idno type="pISSN">0140-6736</idno><idno type="PII">S0140-6736(00)X7275-3</idno><imprint><publisher>ELSEVIER</publisher><date type="published" when="1985"></date><biblScope unit="volume">326</biblScope><biblScope unit="issue">8468</biblScope><biblScope unit="page" from="1330">1330</biblScope><biblScope unit="page" to="1331">1331</biblScope></imprint></monogr></biblStruct></sourceDesc></fileDesc><profileDesc><creation><date>1985</date></creation><langUsage><language ident="en">en</language></langUsage><abstract xml:lang="en"><p>PHNO is a naphthoxazine compound with selective D2 agonist properties and a molecular structure unrelated to the morphine and ergot derivatives that have been used to treat Parkinson's disease. A double-blind, dose-ranging study on 8 patients showed that it is effective in the treatment of parkinsonism; its duration of effect of up to 6 h could make it useful for patients who experience wearing-off reactions with levodopa.</p></abstract></profileDesc><revisionDesc><change when="1985">Published</change></revisionDesc></teiHeader></istex:fulltextTEI><json:item><extension>txt</extension><original>false</original><mimetype>text/plain</mimetype><uri>https://api-v5.istex.fr/document/3F63D38FCCAE9F923B30538459CCC8C55B38697D/fulltext/txt</uri></json:item></fulltext><metadata><istex:metadataXml wicri:clean="Elsevier, elements deleted: tail"><istex:xmlDeclaration>version="1.0" encoding="utf-8"</istex:xmlDeclaration><istex:docType PUBLIC="-//ES//DTD journal article DTD version 4.5.2//EN//XML" URI="art452.dtd" name="istex:docType"></istex:docType><istex:document><converted-article version="4.5.2" docsubtype="fla"><item-info><jid>LANCET</jid><aid>85926273</aid><ce:pii>S0140-6736(85)92627-3</ce:pii><ce:doi>10.1016/S0140-6736(85)92627-3</ce:doi><ce:copyright type="unknown" year="1985"></ce:copyright></item-info><head><ce:dochead><ce:textfn>Preliminary Communication</ce:textfn></ce:dochead><ce:title>(+)-4-PROPYL-9-HYDROXYNAPHTHOXAZINE (PHNO), A NEW DOPAMINOMIMETIC, IN TREATMENT OF PARKINSONISM</ce:title><ce:author-group><ce:author><ce:given-name>A.Jon</ce:given-name><ce:surname>Stoessl</ce:surname></ce:author><ce:author><ce:given-name>E.</ce:given-name><ce:surname>Mak</ce:surname></ce:author><ce:author><ce:given-name>DonaldB.</ce:given-name><ce:surname>Calne</ce:surname></ce:author><ce:affiliation><ce:textfn>Division of Neurology, Department of Medicine, University of British Columbia Health Sciences Centre Hospital, 2211 Wesbrook Mall, Vancouver, British Columbia V6T 1W5, Canada</ce:textfn></ce:affiliation></ce:author-group><ce:abstract><ce:section-title>Abstract</ce:section-title><ce:abstract-sec><ce:simple-para>PHNO is a naphthoxazine compound with selective D2 agonist properties and a molecular structure unrelated to the morphine and ergot derivatives that have been used to treat Parkinson's disease. A double-blind, dose-ranging study on 8 patients showed that it is effective in the treatment of parkinsonism; its duration of effect of up to 6 h could make it useful for patients who experience wearing-off reactions with levodopa.</ce:simple-para></ce:abstract-sec></ce:abstract></head></converted-article></istex:document></istex:metadataXml><mods version="3.6"><titleInfo><title>(+)-4-PROPYL-9-HYDROXYNAPHTHOXAZINE (PHNO), A NEW DOPAMINOMIMETIC, IN TREATMENT OF PARKINSONISM</title></titleInfo><titleInfo type="alternative" contentType="CDATA"><title>(+)-4-PROPYL-9-HYDROXYNAPHTHOXAZINE (PHNO), A NEW DOPAMINOMIMETIC, IN TREATMENT OF PARKINSONISM</title></titleInfo><name type="personal"><namePart type="given">A.Jon</namePart><namePart type="family">Stoessl</namePart><affiliation>Division of Neurology, Department of Medicine, University of British Columbia Health Sciences Centre Hospital, 2211 Wesbrook Mall, Vancouver, British Columbia V6T 1W5, Canada</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">E.</namePart><namePart type="family">Mak</namePart><affiliation>Division of Neurology, Department of Medicine, University of British Columbia Health Sciences Centre Hospital, 2211 Wesbrook Mall, Vancouver, British Columbia V6T 1W5, Canada</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">DonaldB.</namePart><namePart type="family">Calne</namePart><affiliation>Division of Neurology, Department of Medicine, University of British Columbia Health Sciences Centre Hospital, 2211 Wesbrook Mall, Vancouver, British Columbia V6T 1W5, Canada</affiliation><role><roleTerm type="text">author</roleTerm></role></name><typeOfResource>text</typeOfResource><genre type="research-article" displayLabel="Full-length article"></genre><originInfo><publisher>ELSEVIER</publisher><dateIssued encoding="w3cdtf">1985</dateIssued><copyrightDate encoding="w3cdtf">1985</copyrightDate></originInfo><language><languageTerm type="code" authority="iso639-2b">eng</languageTerm><languageTerm type="code" authority="rfc3066">en</languageTerm></language><physicalDescription><internetMediaType>text/html</internetMediaType></physicalDescription><abstract lang="en">PHNO is a naphthoxazine compound with selective D2 agonist properties and a molecular structure unrelated to the morphine and ergot derivatives that have been used to treat Parkinson's disease. A double-blind, dose-ranging study on 8 patients showed that it is effective in the treatment of parkinsonism; its duration of effect of up to 6 h could make it useful for patients who experience wearing-off reactions with levodopa.</abstract><note type="content">Section title: Preliminary Communication</note><relatedItem type="host"><titleInfo><title>The Lancet</title></titleInfo><titleInfo type="abbreviated"><title>LANCET</title></titleInfo><genre type="journal">journal</genre><originInfo><dateIssued encoding="w3cdtf">19851214</dateIssued></originInfo><identifier type="ISSN">0140-6736</identifier><identifier type="PII">S0140-6736(00)X7275-3</identifier><part><date>19851214</date><detail type="issue"><title>Originally published as Volume 2, Issue 8468</title></detail><detail type="volume"><number>326</number><caption>vol.</caption></detail><detail type="issue"><number>8468</number><caption>no.</caption></detail><extent unit="issue pages"><start>1319</start><end>1374</end></extent><extent unit="pages"><start>1330</start><end>1331</end></extent></part></relatedItem><identifier type="istex">3F63D38FCCAE9F923B30538459CCC8C55B38697D</identifier><identifier type="DOI">10.1016/S0140-6736(85)92627-3</identifier><identifier type="PII">S0140-6736(85)92627-3</identifier><recordInfo><recordContentSource>ELSEVIER</recordContentSource></recordInfo></mods></metadata></istex></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Canada/explor/ParkinsonCanadaV1/Data/Istex/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000738 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Istex/Corpus/biblio.hfd -nk 000738 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Canada
|area= ParkinsonCanadaV1
|flux= Istex
|étape= Corpus
|type= RBID
|clé= ISTEX:3F63D38FCCAE9F923B30538459CCC8C55B38697D
|texte= (+)-4-PROPYL-9-HYDROXYNAPHTHOXAZINE (PHNO), A NEW DOPAMINOMIMETIC, IN TREATMENT OF PARKINSONISM
}}
| This area was generated with Dilib version V0.6.29. |  |